2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Seth Taylor

Session 5 – A New Paradigm in Biotech Innovation & Investment
Date: 22 July (Wednesday) 15:40 – 17:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Seth Taylor

CBO & CFO
​SmartLabs


Seth has more than 17 years of industry experience that combines business development, corporate advisory services, and the founding of life science companies.

As Managing General Partner of Vectur LLC and as Principal at TSG Partners, Seth developed growth strategies and worked on a wide range of tactical mandates for leading life science companies. He was co-founder of Molecularware, Inc., a life science information company. Prior to that, he served as a business development executive at Packard Bioscience.

Seth holds a PhD in Molecular Biology from Johns Hopkins University and an MBA from the MIT Sloan School of Management.


Speech title & Synopsis

Accelerating Taiwan Biotechs 

The SmartLabs Global Launch Program is a partnership with ITRI/MOST to support pre-funded to venture-backed Taiwan-based biotech companies in their commercialization efforts in the US and other global markets.  The program builds from the success of SmartLabs Lab-as-a-Service offering in helping the launch of top US biotech companies.  The Global Launch Program incorporates three elements: Training, Mentorship, and a Boston Rotation.  SmartLabs established an office in Hsinchu to support the program. Taiwan offers SmartLabs the unique combination of a world-class university, a leading hospital system, and a history of working effectively with global companies.  
 
The world wide pandemic of COVID-19 has caused the loss of many lives by now, the situation is not eased today. The trend of developing therapeutics to treat COVID-19 is by repurposing existing approved drugs and late stage development drugs to be most desirable since the discovery of any new treatment can not meet the urgent needs today.
 
Silmitasertib (CX-4945) has been shown high safety profile and tolerability in over 200 patients in phase I and II trials conducted over the past. Recently, it was tested to have strong effects to inhibit SARS-CoV-2 replication and reduction of cytokine storm. Cytokine storm is known to occur at severe stage leading to organ failure and death. By far, Silmitasertib (CX-4945) is the only drug known today to demonstrate dual actions in reduce both viral replication and cytokine storm.